Recruiting studies: Moderate Hepatic Impairment

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Im
Phase 1 · 22 location(s) · Taiho Oncology, Inc. · NCT04953910 Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Partici
Phase 1 · 8 location(s) · Eisai Co., Ltd. · NCT04271488 Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
Phase 1 · 1 location(s) · Zydus Therapeutics Inc. · NCT06825559 A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
Phase 1 · 4 location(s) · AstraZeneca · NCT07546760 A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants
Phase 1 · 3 location(s) · Bristol-Myers Squibb · NCT07248839 Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Phase 1 · 8 location(s) · Novartis Pharmaceuticals · NCT07422610 Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Phase 1 · 2 location(s) · Exelixis · NCT06962332 A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Modera
Phase 1 · 3 location(s) · Eli Lilly and Company · NCT07165002 A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Gr
Phase 2 · 52 location(s) · AbbVie · NCT06682988 Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Phase 1 · 15 location(s) · Gilead Sciences · NCT04617522 A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
Phase 1 · 3 location(s) · Merck Sharp & Dohme LLC · NCT06442436 A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment
Phase 1 · 1 location(s) · Taisho Pharmaceutical Co., Ltd. · NCT07231029 A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healt
Phase 1 · 3 location(s) · Eli Lilly and Company · NCT07401862 A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
Phase 1 · 4 location(s) · Genentech, Inc. · NCT07144111 A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
Phase 1 · 3 location(s) · Boehringer Ingelheim · NCT07023354 Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Sub
Phase 1 · 1 location(s) · Aligos Therapeutics · NCT07342868 A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets i
Phase 1 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT07694843 A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Imp
Phase 1 · 2 location(s) · AstraZeneca · NCT07343960 To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
Phase 1 · 2 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT07480824 A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Mode
Phase 1 · 4 location(s) · Incyte Corporation · NCT07559474 A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
Phase 1 · 4 location(s) · Pfizer · NCT07231991 Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological
Phase 1 · 4 location(s) · Acrotech Biopharma Inc. · NCT07036133 Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
Phase 1 · 1 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07152288

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.